Covered recipient · General Payments record
JOHN DAVID HANNA
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2022–2024
$373.16
- Reported across 17 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $351.61 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $73.84 | 3 |
| Lundbeck LLC | $48.02 | 2 |
| Neurocrine BioSciences, Inc. | $47.78 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $42.00 | 2 |
| ARGENX US, INC. | $26.27 | 1 |
| Biogen, Inc. | $21.35 | 1 |
| ACADIA Pharmaceuticals Inc | $21.16 | 1 |
| Neurelis, Inc. | $21.08 | 1 |
| Genentech USA, Inc. | $18.41 | 1 |
| PFIZER INC. | $18.04 | 1 |
| CYCLE PHARMACEUTICALS INC | $13.66 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.95 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103874848 | CMS |
| ABBVIE INC. | $22.41 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103874850 | CMS |
| ABBVIE INC. | $26.48 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103874852 | CMS |
| ACADIA Pharmaceuticals Inc | $21.16 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147973262 | CMS |
| ARGENX US, INC. | $26.27 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142119813 | CMS |
| Biogen, Inc. | $21.35 | 11/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104811705 | CMS |
| Cycle Pharmaceuticals Inc | $13.66 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154920168 | CMS |
| Genentech USA, Inc. | $18.41 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133036789 | CMS |
| Lundbeck LLC | $23.47 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145922956 | CMS |
| Lundbeck LLC | $24.55 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145922958 | CMS |
| Neurelis, Inc. | $21.08 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145643036 | CMS |
| Neurocrine Biosciences, Inc. | $21.88 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150851786 | CMS |
| Neurocrine Biosciences, Inc. | $25.90 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150837409 | CMS |
| Novartis Pharmaceuticals Corporation | $21.00 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086960417 | CMS |
| Novartis Pharmaceuticals Corporation | $21.00 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086960429 | CMS |
| PFIZER INC. | $18.04 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131950164 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.